Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...

Key companies operating in this space include Sage Therapeutics Inc., Cipla Limited, Sun Pharmaceutical Industries Ltd., Anikem Laboratories, Intas Pharmaceuticals Ltd., Mylan N.V., Sumika Fine ...

Organon acquired regulatory and commercial rights in the United States for TOFIDENCE ™, a biosimilar to ACTEMRA ®, for intravenous infusion from Biogen. TOFIDENCE, the first approved ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Biogen recently received Fast Track designation from the FDA for its Alzheimer's therapy, BIIB080, signaling a significant advancement in its drug development ambitions. However, despite these ...

TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In this article, we are going to take a look at where Soleno Therapeutics Inc. (NASDAQ:SLNO) stands against other stocks that outperformed broader market last week. Wall Street’s main indices ...